Cosmelan vs Dermamelan vs Chemical Peels: A Clinician's Comparison for Melasma

Every melasma patient in India eventually asks the same question: "Doctor, should I do Cosmelan?" The answer is rarely as simple as yes or no. Cosmelan is a well-marketed system with solid clinical data, but it is one option among several, and it is not always the best fit — clinically or economically — for Indian skin or Indian practice realities.

This guide walks through four credible melasma approaches in the Indian practitioner's toolkit, what the evidence actually supports, and how to pick between them for a specific patient sitting in front of you.

What Cosmelan Actually Is

Cosmelan is a two-phase depigmentation system. Phase 1 is a clinic-applied mask containing azelaic acid, kojic acid, phytic acid, arbutin, and ascorbic acid, left on for 8–12 hours before home removal. Phase 2 is a 6-month take-home maintenance cream applied by the patient 1–3 times daily.

The original formulation contained hydroquinone. Current versions (Cosmelan 2) are hydroquinone-free, relying on the multi-agent tyrosinase inhibition combination for efficacy.

What the evidence supports: Cosmelan produces measurable melasma area and severity index (MASI) reduction in 70–80% of patients at 3 months, with maintained improvement at 6 months when the home regimen is followed.

What Cosmelan is not: A one-session solution. The marketing often implies dramatic single-application results. The clinical reality is that the home maintenance phase does most of the work, and patient compliance over 6 months determines the outcome.

Dermamelan: The Higher-Concentration Cousin

Dermamelan is produced by the same company (mesoestetic) with higher concentrations of the active ingredients. The protocol is similar — clinic mask followed by home maintenance — but the treatment intensity is higher.

When Dermamelan makes sense: Resistant melasma that has failed Cosmelan or equivalent systems, dermal-predominant melasma visible on Wood's lamp with deeper distribution, and patients who need a faster intensity curve.

When it does not: Fitzpatrick V–VI with active inflammation. The higher active load in Dermamelan increases PIH risk in deeply pigmented Indian skin. The choice is often between patient frustration with slower Cosmelan results versus iatrogenic PIH from aggressive Dermamelan — neither outcome is good.

Chemical Peels: The Multi-Pathway Alternative

The depigmentation-system-versus-peel debate frames the two as competing modalities. They are not. Peels and depigmentation systems address overlapping but distinct mechanisms, and used correctly they are complementary.

Multi-pathway peels like the Prodermic 580 Yellow Peel deliver retinol, glycolic, lactic, and kojic in a single clinic application, targeting epidermal turnover acceleration, corneocyte desquamation, and tyrosinase inhibition simultaneously. The session-to-session progress is faster than Cosmelan because the epidermal clearance component is more aggressive.

For lighter, recent-onset melasma, a 4–6 session course of a multi-pathway peel often achieves results comparable to Cosmelan at roughly 30–40% of the total patient cost.

The Honest Comparison Table

Factor	Cosmelan 2	Dermamelan	Multi-pathway peels	Melasmonil peel
Sessions	1 clinic + 6mo home	1 clinic + 6mo home	4–6 clinic sessions	4–6 clinic sessions
Total patient cost (India)	₹35,000–50,000	₹45,000–65,000	₹15,000–25,000	₹18,000–28,000
Time to visible change	4–8 weeks	3–6 weeks	2–4 weeks	3–5 weeks
Downtime (clinic phase)	5–7 days peeling	7–10 days peeling	3–5 days peeling	2–4 days peeling
Fitzpatrick V–VI safety	Moderate	Low	High with appropriate protocol	High
Home compliance burden	Very high	Very high	Low	Moderate
Best for	Stable, motivated patient	Resistant melasma in lighter skin	Recent, active melasma	Mixed melasma + PIH

How to Actually Choose for a Patient

The decision tree most experienced Indian dermatologists use, formalised:

Step 1: What is the Wood's lamp pattern?

• Epidermal-predominant melasma (pigment enhanced under Wood's): responds well to chemical peels and topical depigmentation. Any of the four options can work.
• Dermal-predominant melasma (pigment less visible under Wood's): requires longer courses, often combination therapy. Dermamelan or combined peel + serum regimens perform better than single-modality approaches.
• Mixed pattern: the majority of Indian melasma patients. Combination protocols are the rule, not the exception.

Step 2: What is the patient's budget and compliance profile?

• High budget, high compliance: Cosmelan or Dermamelan is a reasonable premium choice.
• Moderate budget, moderate compliance: Multi-pathway peel courses produce comparable results with less home-regimen burden.
• Low budget: Peel courses are substantially cheaper per visible result, and skipping the expensive home cream does not destroy the outcome.

Step 3: What is the Fitzpatrick type?

• Fitzpatrick III–IV: full range of options, including Dermamelan.
• Fitzpatrick V: Cosmelan over Dermamelan, or multi-pathway peels with appropriate priming.
• Fitzpatrick VI: avoid Dermamelan; prefer gentle multi-pathway peels like Melasmonil combined with tyrosinase-inhibiting serums.

Step 4: How much has the patient already tried?

A patient who has failed two previous peel courses or a previous Cosmelan cycle is signalling resistance. Escalating intensity alone rarely works — the failure is usually a missed contributing factor (unidentified UV exposure, occult hormonal trigger, incorrect diagnosis). Escalate the diagnostic workup before escalating the treatment.

Prodermic 612 Cosmelan-Forte: When It Applies

The Prodermic 612 protocol is positioned for practitioners who want Cosmelan-class multi-agent depigmentation intensity with the in-clinic protocol flexibility of a chemical peel course. It differs from the original Cosmelan system in two key ways:

• Clinic-delivered across 4–6 sessions rather than one large application, which reduces the peak inflammatory load at each visit and therefore the PIH risk in darker skin types.
• No mandatory 6-month home regimen — maintenance is recommended but the protocol does not collapse without perfect home compliance.

For the practitioner, this means a more predictable session schedule and the ability to calibrate intensity session-to-session based on patient response, rather than committing to a single large intervention and hoping the home regimen sustains it.

The Maintenance Question

Regardless of which protocol you choose, melasma is a chronic condition. The clinic-phase outcome is maintained only if post-treatment protocols control the downstream triggers:

1. Daily SPF 50+ with visible-light protection (iron oxide tints). Standard SPF that only blocks UV is insufficient for melasma maintenance.
2. A tyrosinase-inhibiting topical 2–3 times per week indefinitely. This can be a low-concentration kojic, tranexamic acid, or niacinamide preparation.
3. Quarterly maintenance peels at a reduced intensity.

Patients who stop all maintenance after 6 months have recurrence rates above 60% within two years. Patients who maintain a minimal regimen have recurrence rates closer to 20%. The clinic-phase choice matters less than the maintenance reality — a lesser peel with good maintenance beats Cosmelan with no follow-through.

Key Takeaways

1. There is no single "best" melasma system. Cosmelan, Dermamelan, and well-designed peel courses all produce similar 6-month outcomes in appropriate patients.
2. Fitzpatrick type matters more than concentration. In V–VI, choose gentler multi-session protocols over high-intensity single interventions.
3. Cost-to-outcome is dramatically better for multi-pathway peel courses than for branded depigmentation systems in the Indian market.
4. Maintenance determines recurrence. Clinic-phase choice is session-1 work; maintenance is 95% of the long-term outcome.
5. Escalate workup before escalating treatment. Resistant melasma is usually a missed trigger, not an undertreated lesion.